"Injections, Subcutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
Descriptor ID |
D007279
|
MeSH Number(s) |
E02.319.267.530.620
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Injections, Subcutaneous".
Below are MeSH descriptors whose meaning is more specific than "Injections, Subcutaneous".
This graph shows the total number of publications written about "Injections, Subcutaneous" by people in this website by year, and whether "Injections, Subcutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 3 | 3 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 3 | 3 |
2001 | 0 | 4 | 4 |
2002 | 0 | 2 | 2 |
2003 | 0 | 2 | 2 |
2004 | 0 | 5 | 5 |
2005 | 0 | 2 | 2 |
2006 | 0 | 5 | 5 |
2007 | 0 | 6 | 6 |
2008 | 0 | 2 | 2 |
2009 | 0 | 4 | 4 |
2010 | 0 | 3 | 3 |
2011 | 0 | 3 | 3 |
2012 | 0 | 2 | 2 |
2013 | 0 | 3 | 3 |
2014 | 0 | 4 | 4 |
2015 | 0 | 3 | 3 |
2016 | 0 | 6 | 6 |
2017 | 0 | 4 | 4 |
2018 | 0 | 1 | 1 |
2019 | 0 | 3 | 3 |
2020 | 0 | 6 | 6 |
2021 | 0 | 2 | 2 |
2022 | 0 | 2 | 2 |
2024 | 0 | 3 | 3 |
2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Injections, Subcutaneous" by people in Profiles.
-
Anticipation, perception, and recollection of acute pain from local anesthesia injection prior to Mohs surgery. Arch Dermatol Res. 2025 Feb 25; 317(1):490.
-
Subcutaneous administration of drugs and hydration in acute palliative care units: Physician attitudes and beliefs in the United States and Canada. Palliat Support Care. 2024 Jun; 22(3):535-538.
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):913-925.
-
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 Jun 27; 390(24):2274-2283.
-
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024 May; 127:104390.
-
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
-
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 07; 10(7):1835-1843.
-
Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC). Contraception. 2022 08; 112:11-13.
-
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022 02; 61(2):263-280.
-
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021 03 30; 12(1):1967.